SARS MERS, HEK
HEK293
Protein is >85% pure as determined SDS-PAGE.
Description
The HEK293 derived recombinant protein contains the SARS MERS Spike Glycoprotein S1, amino acids 18-725 fused to dimeric Fc tag at N-terminal having a total Mw of 215.7 kDa.
Product Specs
HEK293
Purified by Protein-G chromatographic technique.
Product Science Overview
The spike glycoprotein (S protein) is a crucial component of coronaviruses, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). This protein plays a vital role in the virus’s ability to infect host cells. The recombinant form of the spike glycoprotein-S1 (S1 subunit) is used extensively in research and vaccine development due to its importance in viral entry and immune response.
The spike glycoprotein is a large, type I transmembrane protein that protrudes from the viral envelope. It is composed of two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which is responsible for binding to the host cell receptor. For SARS-CoV and SARS-CoV-2, this receptor is the angiotensin-converting enzyme 2 (ACE2), while for MERS-CoV, it is dipeptidyl peptidase 4 (DPP4).
The S1 subunit’s RBD is highly specific and facilitates the initial attachment of the virus to the host cell. This binding is the first step in the viral entry process, followed by the S2 subunit mediating the fusion of the viral and host cell membranes, allowing the viral genome to enter the host cell.
Recombinant S1 glycoprotein is produced using various expression systems, such as mammalian cells, insect cells, or yeast. This recombinant protein is used in several applications, including:
- Vaccine Development: The S1 subunit is a primary target for vaccine development due to its role in eliciting neutralizing antibodies. Vaccines aim to induce an immune response that can block the interaction between the S1 subunit and the host cell receptor, preventing infection.
- Diagnostic Tools: Recombinant S1 glycoprotein is used in serological assays to detect antibodies against SARS-CoV, MERS-CoV, and SARS-CoV-2 in patient samples. These assays help in diagnosing past infections and assessing immune responses.
- Therapeutic Research: The S1 subunit is studied to develop therapeutic agents that can inhibit viral entry. Monoclonal antibodies targeting the RBD of the S1 subunit have shown promise in neutralizing the virus and are being explored as potential treatments.
The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the significance of the spike glycoprotein in viral pathogenesis and immune response. The S1 subunit of SARS-CoV-2 has been extensively studied to understand its structure, function, and interactions with the host immune system. This knowledge has been crucial in the rapid development of vaccines and therapeutic agents to combat COVID-19 .
